Paclitaxel-eluting composite fibers: Drug release and tensile mechanical properties

Journal of Biomedical Materials Research - Part A

Volumn 84, Issue 2, 2008, Pages 313-323

  Zilberman, Meital ^a   Kraitzer, Amir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Composite fibers; Controlled drug release; Paclitaxel; Poly(DL lactic co glycolic acid); Porous structure

Indexed keywords

BIOMEDICAL ENGINEERING; COMPOSITE MATERIALS; FIBERS; TENSILE PROPERTIES;

COMPOSITE FIBERS; CONTROLLED DRUG RELEASE; PACLITAXEL; POLYDL-LACTIC-CO- GLYCOLIC ACID; POROUS STRUCTURE;

DRUG DELIVERY;

PACLITAXEL; POLYGLACTIN;

ARTICLE; CONTROLLED DRUG RELEASE; DEGRADATION; DIFFUSION; DRUG ELUTING STENT; EMULSION; FIBER; FREEZE DRYING; POROSITY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TENSILE STRENGTH;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; FREEZE DRYING; MICROSCOPY, ELECTRON, SCANNING; NYLONS; PACLITAXEL; POROSITY; SOLUBILITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; TENSILE STRENGTH;

EID: 38049047213     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31286     Document Type: Article

References (34)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M and others. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P and others. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
3. Stefanidis IK, Tolis VA, Sionis DG, Michalis LK. Development in intracoronary stents. Hellenic J Cardiol 2002;43:63-67.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
5. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 1994;107:179-185.
6. Honda Y, Grube E, de La Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380-383.
7. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S, Montorfano M, Carlino M, Briguori C, Pagnotta P, Albiero R, Corvaja N, Colombo A. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002;105:1883-1886.
8. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Pompa JJ. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-1613.
9. Silber S, Grudel E. The Boston Scientific antipropliferative, Paclitaxel eluting stent (TAXUS). In: Serruys PW, Rensing BJ, editors. Handbook of Coronary Stents. London: Martin Dunitz; 2001. p 311-319.
10. Dhanikula AB, Panchagnula R. Localized paclitaxel delivery. Int J Pharm 1999;183:85-100.
11. AHFS Drug Information. American Society of Health System Pharmacists. Bethseda; 1989. p 1075-1086.
12. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-1014.
13. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32:780-786.
14. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.
15. Suh H, Jeong B, Rathi R, Kim SW. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/ glycolide) nanospheres. J Biomed Mater Res 1998;42:331-338.
16. Alexis F, Venkatraman SS, Rath SK, Boey F. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 2004;98:67-74.
17. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
18. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, Munzel T, Belardi J, Ruzyllo W, Bilodeau L, Kelbaek H, Ormiston J, Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME, Colombo A. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004;109:196-200.
19. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
20. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Pompa JJ, Russel ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
21. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Nakamura T, Fujita S, Takeda S, Motohara S, Uehata H. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 2003;5:13-16.
22. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
23. Tamai H, Igaki K, Tsuji T. A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J interv cardiol 1999;12:443-449.
24. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995;118:213-221.
25. Nguyen KT, Su SH, Zilberman M, Bohluli P, Frenkel P, Tang L, Eberhart RC. Biomaterials and stent technology. In: Yaszemski M, Rantolo D, Lewandrowski KU, Hasirci V, Altobelli D, Wise D, editors. Tissue engineering and novel delivery systems New York: Marcel Dekker; 2004. p 107-130.
26. Zilberman M, Schwade ND, Eberhart RC. Protein-loaded bioresorbable fibers and expandable stents: Mechanical properties and protein release. J Biomed Mater Res B Appl Biomater 2004;69:1-10.
27. Su SH, Chao RY, Landau CL, Nelson KD, Timmons RB, Meidell RS, Eberhart RC. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann Biomed Eng 2003;31:667-677.
28. Zilberman M, Eberhart RC. Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng 2006;8:153-180.
29. Levy Y, Zilberman M. Novel bioresorbable composite fiber structures loaded with proteins for tissue regeneration applications: microstructure and protein release. J Biomed Mater Res A 2006;79:779-787.
30. Kraitzer A, Zilberman M. Paclitaxel-loaded composite fibers: Microstructure and emulsion stability. J Biomed Mater Res A 2007;81:427-436.
31. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003;86:33-48.
32. Liggins RT, Burt HM. Paclitaxel loaded poly(L-lactic acid) (PLLA) microspheres II. The effect of processing parameters on microsphere morphology and drug release kinetics. Int J Pharm 2004;281:103-106.
33. Zilberman M, Sofer M. A mathematical model for predicting controlled release of bioactive agents from composite fiber structures. J Biomed Mater Res part A 2007;80:679-686.
34. Zilberman M, Nelson KD, Eberhart RC. Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiber-based stents. J Biomed Mater Res B Appl Biomater 2005;74:792-799.